Albert Einstein College of Medicine

Cephalon, Inc.

Other

Stuart C Apfel

John A Kessler

Michael E Lewis

Stanley M Crain

Ke-fei Shen

This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .alpha. (TFG-.alpha.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.

Use of growth factors to treat drug-inducted neuropathy

The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.

Prevention and treatment of peripheral neuropathy

This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.

Use of NGF growth factors to treat drug-induced neuropathy

This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.

Use of excitatory opioid receptor antagonists to prevent growth

The invention features a method of preventing or treating a peripheral neuropathy that results from a systemic disease (e.g., post-polio syndrome) or a toxic agent (e.g., a chemotherapeutic agent), and that is not caused by an abnormal insulin level in a mammal. The method involves administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to the mammal.

Growing community of inventors

West Hempstead, NY, United States of America

Stuart C Apfel